Methods of treating stroke and traumatic brain injury using humanized AQC2 anti-VLA-1 antibodies

A method of treating a traumatic brain injury (TBI) in a subject, the method comprising administering to the subject a humanized AQC2 anti-VLA-1 (Very Late Activation Antigen-I) antibody, or an antigen-binding fragment thereof, wherein the anti-VLA-1 antibody, or antigen-binding fragment thereof, is first administered within 48 hours of the TBI, and wherein the anti-VLA-1 antibody, or antigen-binding fragment thereof, reduces infarct size in a hemisphere affected by the TBI, such that the percentage of the hemisphere infarcted is 40% or less, and wherein the anti-VLA-1 antibody or antigen-binding fragment thereof is administered at a dosage from 0.1 mg/kg per day to 5 mg/kg per day.